New drug combo aims to boost stem cell transplant success in tough lymphoma

NCT ID NCT07225985

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new combination of two chemotherapy drugs (pralatrexate and bendamustine) plus low-dose radiation to the whole body before a donor stem cell transplant. The goal is to see if this approach is safe and helps more people with relapsed or refractory T-cell lymphoma get to transplant. About 50 adults will take part in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pralatrexate and bendamustine
What this could lead to: If this works, it could offer a new, less intense way to prepare patients for a donor stem cell transplant, potentially improving outcomes for those with hard-to-treat T-cell lymphoma.
What could go wrong: This is an early phase I/II trial with only 50 participants, so results are preliminary. The combination may cause serious side effects, and it's not yet known if it will be better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT T-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT T-CELL NON-HODGKIN LYMPHOMA REFRACTORY T-CELL NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.